Immatics News and Activities

Immatics is a company listed under the stock ticker IMTX (DE).

Immatics has a direct presence in 2 countries.

View the org chart displaying its 52 main executives

Most searched biographies at Immatics

• Harpreet Singh, Chief Executive Officer and Director
• Heather Mason, Director
• Peter Chambré, Chairman of the Board

Popular executive movements at Immatics

• Andy Deig has joined the company as Senior Vice President, Finance  (posted on April 16 2026).
• Amie Krause has joined the company as Chief People Officer  (posted on October 28 2025).
• Venkat Ramanan has joined the company as Chief Financial Officer  (posted on October 1 2025).

Create your alert
to follow the executive moves at Immatics.

Immatics has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Immatics

• Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer | Immatics N.V.
• Immatics Announces First Quarter 2022 Financial Results and Business Update | Immatics N.V.
• Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs | Immatics N.V.
• Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors | Immatics N.V.
• Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors | Immatics N.V.
• German Press Releases | Immatics N.V.
• Immatics Announces Full Year 2021 Financial Results and Corporate Update | Immatics N.V.
• Press Releases | Immatics N.V.
• Immatics Appoints Cedrik Britten as Chief Medical Officer - Immatics
• Immatics Appoints Thomas Ulmer as Chief Financial Officer - Immatics
• View more press releases Close

Social media about Immatics

• Immatics on Wikipedia, Google News & Yahoo Finance
• Immatics on LinkedIn, X (Twitter) & YouTube